Navigation Links
Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
Date:9/6/2011

SEATTLE, Sept. 6, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Rodman and Renshaw 13th Annual Healthcare Conference taking place in New York City next week.  The presentation is scheduled for Tuesday, September 13, 2011 at 2:00 p.m. Eastern Time.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
6. Omeros Appoints New Vice President of Clinical Development
7. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
8. Omeros Commences Initial Public Offering of Common Stock
9. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 The new ... a comprehensive library of reports on Valero Energy , ... fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... production to go green. Ethanol today, even though touted as ...
(Date:3/27/2017)... MA (PRWEB) , ... March 27, 2017 , ... ... a method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, ... may lead to new and improved ways of treating coronary artery disease (CAD). ...
(Date:3/27/2017)... March 27, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... option for U.S. consumers who want to have their ... has signed strategic alliance agreements with partners across the ... benefits, and if approved, will supply and bill the ...
(Date:3/24/2017)... , March 24, 2017 MiMedx Group, ... company utilizing human placental tissue allografts and patent-protected processes ... multiple sectors of healthcare, announced today  that it will ... New York , NY.  Parker H. "Pete" Petit, ... Financial Officer, Christopher M. Cashman , EVP and ...
Breaking Biology Technology:
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
Breaking Biology News(10 mins):